Only 1 of 25 cancer drug developers fairly included minority patients over five-year window, BMJ analysis finds

New clinical trial diversity plans, which FDA will soon explain further, were featured in the government spending package that President Joe Biden signed late last week and are coming at a time when they’re very much needed, according to a new analysis published in the BMJ...

Click to view original post